Sera Prognostics (SERA) Set to Post Quarterly Earnings on Wednesday

Sera Prognostics (NASDAQ:SERA) is anticipated to announce its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect Sera Prognostics to post earnings of ($0.14) per share and revenue of $0.07 million for the quarter. Individuals can find conference call details on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Wednesday, November 4, 2026 at 5:00 PM ET.

Sera Prognostics (NASDAQ:SERA) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.03). Sera Prognostics had a negative net margin of 47,475.72% and a negative return on equity of 46.71%. The business had revenue of $0.03 million for the quarter, compared to the consensus estimate of $0.07 million. On average, analysts expect Sera Prognostics to post ($0.62) EPS for the current fiscal year and ($0.52) EPS for the next fiscal year.

Sera Prognostics Stock Performance

Sera Prognostics stock traded up $0.03 during mid-day trading on Tuesday, hitting $2.02. 943 shares of the company traded hands, compared to its average volume of 43,806. The stock has a fifty day moving average price of $2.05 and a 200-day moving average price of $2.14. The stock has a market cap of $79.49 million, a price-to-earnings ratio of -3.01 and a beta of 1.06. Sera Prognostics has a one year low of $1.56 and a one year high of $3.85.

Insider Transactions at Sera Prognostics

In other Sera Prognostics news, CEO Zhenya Lindgardt sold 20,139 shares of the stock in a transaction that occurred on Tuesday, September 8th. The shares were sold at an average price of $2.00, for a total transaction of $40,278.00. Following the transaction, the chief executive officer directly owned 844,870 shares in the company, valued at $1,689,740. This trade represents a 2.33% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 39,661 shares of company stock valued at $79,563 over the last ninety days. 11.30% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings lowered Sera Prognostics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $5.50.

Sera Prognostics Company Profile

Sera Prognostics, Inc is a women’s health diagnostics company focused on improving pregnancy outcomes through biomarker-based testing. The company uses proteomics, bioinformatics and clinical data to develop diagnostic and prognostic products designed to identify risks associated with pregnancy complications.

Its lead product is the PreTRM test, a blood-based test intended to assess a pregnant woman’s risk of spontaneous preterm birth in a singleton pregnancy. The test measures specific protein biomarkers and is designed to provide physicians with information that may support risk assessment, patient management and care planning during pregnancy.

Founded in 2008 and headquartered in Salt Lake City, Utah, Sera Prognostics primarily serves the U.S.